Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000723538 | SCV000110106 | pathogenic | not provided | 2018-03-06 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000078266 | SCV000825681 | pathogenic | Fabry disease | 2022-06-01 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Met42 amino acid residue in GLA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 8875188, 18205205, 19287194, 23935525). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this missense change affects GLA function (PMID: 26415523). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 92541). This missense change has been observed in individual(s) with Fabry disease (PMID: 12175777, 15776423; Invitae). This sequence change replaces methionine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 42 of the GLA protein (p.Met42Thr). |
Genome- |
RCV000078266 | SCV002054458 | pathogenic | Fabry disease | 2021-07-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000078266 | SCV002787368 | pathogenic | Fabry disease | 2021-10-20 | criteria provided, single submitter | clinical testing |